Mizuho Securities Initiates Kite Pharma With Buy

by Monica Gerson, Benzinga Staff Writer

January 9, 2015 8:40 AM | 13 seconds read | Make a Comment

Analysts at Mizuho Securities initiated coverage on shares of

Kite Pharma, Inc.KITE

with a Buy rating. The target price for Kite Pharma is set to $90. Kite Pharma's shares rose 0.08% to close at $71.03 yesterday.

Posted In: Initiation Analyst Ratings Mizuho Securities

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.